The evaluation of immune responses to hepatitis B vaccination in diabetic and non-diabetic haemodialysis patients and the use of tetanus toxoid

Nephrology

Volumn 13, Issue 6, 2008, Pages 487-491

  Ocak, Sabahattin ^a   Eskiocak, Ali Fuat ^b  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b Antakya Haemodialysis Center   (Turkey)

Author keywords

Diabetes mellitus; Haemodialysis; Hepatitis B vaccination; Tetanus toxoid

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; TETANUS TOXOID;

ADOLESCENT; ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; FEMALE; HEMODIALYSIS PATIENT; HEPATITIS B; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEROCONVERSION;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; TETANUS TOXOID; VACCINATION;

EID: 52649154989     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.00936.x     Document Type: Article

References (38)

1. Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian JC. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am. J. Nephrol. 2001 21:300 306.
2. Girndt M, Sester M, Sester U, Kaul H, Kohler H. Defective expression of B7-2 (CD68) on monocytes of dialysis patients correlates to the uraemia associated immune defect. Kidney Int. 2001 59:1382 9.
3. Ray S, Samuel T, Hawker J, Smith SA. Hepatitis B immunisation in renal units in the United Kingdom. BMJ 2002 324:877 8.
4. Liu YL, Kao MT, Huang CC. A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine 2005 23:3957 60.
5. Bel'eed K, Wright M, Eadington D, Farr M, Sellars L. Vaccination against hepatitis B infection in patients with end-stage renal disease. Postagrad Med. J. 2002 78:538 40.
6. Navarro JF, Teruel JL, Mateos ML, Ortuño J. Antibody level after hepatitis B vaccination in hemodialysis patients: Influence of hepatitis C virus infection. Am. J. Nephrol. 1996 16:95 7.
7. Peces R, de la Torre M, Alcazar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am. J. Kidney Dis. 1997 29:239 45.
8. Zuckerman JN, Zuckerman AJ, Symington I, Du W, Williams A, Dickson B. Evaluation of new hepatitis B triple antigen vaccine in inadequate responders to current vaccines. Hepatology 2001 34:792 802.
9. Strue J, Aranson B, Frening B. Seroconversion after additional vaccine doses to nonresponders three doses of intradermally administered recombinant hepatitis B vaccine. Scand. J. Infect. Dis. 1994 26:468 70.
10. Kayatas M. Levamisole treatment enhances protective antibody response to hepatitim B vaccination in hemodialysis patients. Artif. Organs 2002 26:492.
11. Sonmez E, Sonmez AS, Bayindir Y, Coskun D, Ariturk S. Antihepatitis B response to hepatitis B vaccine administered simultaneously with tetanus toxoid in nonresponder individuals. Vaccine 2002 13:243 6.
12. West DJ, Rabalais GB, Watson B, Keyserling HL, Matthews H, Hesley TM. Antibody responses of healthy infants to concurrent administration of bivalent haemophilus influenzae type b-hepatitis B vaccine with diphteria-tetanus- pertussis, polio and measles-mumps-rubella vaccine. Biodrugs 2001 15:413 18.
13. Omeneca F, Dal-Re R, D'Apuzzo V et al. Reactogenicity of DTPa-HBV/Hib vaccines administered simultaneously at separate sites to infants at 2, 4, and 6 months of age. Vaccine 2001 30:4260 66.
14. Prikazsky V, Boch HL. Higher anti-hepatitis B response with combined DTPw-HBV vaccine compared with separate administration in healthy infants at 3, 4, and 5 months of age in Slovakia. Int. J Clin. Pract. 2001 55:156 61.
15. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001 414:782 7.
16. Pozzilli P, Arduini P, Visalli N et al. Reduced protection against hepatitis B virus following vaccination in patients with type I (insulin-dependent) diabetes. Diabetologia 1987 30:817 19.
17. Alper CA, Kruskall MS, Marcus-Bagley D et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl. J. Med. 1989 321:708 12.
18. Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix-B): A review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003 63:1021 51.
19. Douvin C, Simon D, Charles MA et al. Hepatitis B vaccination in diabetic patients: Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen. Diabetes Care 1997 20:148 54.
20. Elwell RJ, Neumann M, Bailie GR. Factors associated with long-term antibody production induced by hepatitis B vaccine in patients undergoing hemodialysis: A retrospective cohort study. Pharmacotherapy 2003 23:1558 63.
21. Eardley KS, Jones HE, Osman H, Smith SA. Efficacy of the accelerated hepatitis B vaccination schedule used in haemodialysis patients post-exposure to virus: A single-centre experience. Nephrol. Dial. Transplant. 2002 17:1982 7.
22. Charest AF, Grand'Maison A, McDougall J, Goldstein MB. Evolution of naturally acquired hepatitis B immunity in the long-term hemodialysis population. Am. J. Kidney Dis. 2003 42:1193 9.
23. Noborg U, Gusdal A, Horal P, Lindh M. Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection. Scand. J. Infect. Dis. 2000 32:249 52.
24. Lewis-Ximenez LL, Oliveira JM, Mercadante LA et al. Serological and vaccination profile of hemodialysis patients during an outbreak of hepatitis B virus infection. Nephron 2001 87:19 26.
25. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic haemodialysis patients. Am. J. Kidney Dis. 1999 33:356 60.
26. Ahuja TS, Kumar S, Mansoury H, Rodrigues H, Kuo Y-F. Hepatitis B vaccination in human immunodeficiency virüs-infected adults receiving hemodialysis. Kidney Int. 2005 67:1136 41.
27. Latscha BD, Jungers P, Witko-Sarsat V. Immune system dysregulation in uremia: Role of oxidative stress. Blood Purif. 2002 20:481 4.
28. Meier P, Payer E, Blanc E, Wauters JP. Early T-cell activation correlation with expression of apoptosis markers in patients with end stage renal disease. J. Am. Soc. Nephrol. 2002 13:204 12.
29. Sangiorgio L, Attardo T, Gangemi R, Rubino C, Barone M, Lunetta M. Increase frequency of HCV and HBV infection in type 2 diabetic patients. Diabetes Res. Clin. Pract. 2000 48:147 51.
30. Sezer S, Ozdemir FN, Guz G et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant. Proc. 2000 32:607 8.
31. Buti M, Viladomiu L, Jardi R et al. Long-term immunogenecity and efficacy of hepatitis B vaccine in haemodialysis patients. Am. J. Nephrol. 1992 12:144 7.
32. Fleming SJ, Moran DM, Cooksley WG, Faoagali JL. Poor response to a recombinant hepatitis B vaccine in dialysis patients. J. Infect. 1991 22:251 7.
33. Docci D, Cipolloni PA, Mengozzi S, Baldrati L, Capponcini C, Feletti C. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: A 2-year follow-up. Nephron 1992 61:352 3.
34. MacMohan MM, Bistrian BR. Host defences and susceptibility to infection in patients with diabetes mellitus. Infect. Dis Clin. North Am. 1995 9:1 9.
35. Kara IH, Yilmaz ME, Suner A, Kadiroglu AK, Isikoglu B. The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients. Vaccine 2004 22:3963 7.
36. Wismans PJ, van Hattum J, de Gast GC et al. A prospective study of in vitro anti-HBs producing B-cells (Spot-ELISA) following primary and supplementary vaccination with recombinant hepatitis B vaccine in insulin dependent diabetic patients and matched controls. J. Med. Virol. 1991 35:216 22.
37. Egea E, Iglesias A, Salazar M et al. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J. Exp. Med. 1991 173:531 8.
38. Desombere I, Hauser P, Rossau R, Paradijs J, Leroux-Roels G. Nonresponders to hepatitis B vaccine can present envelope particles to T-lymphocytes. J. Immunol. 1995 154:520 29.